October 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
Diagnosis & Disease Information
Labcorp Launches Test to Identify Neuronal Damage Due to Disease or Injury
The biomarker test measures NfL levels through standard blood collection.
Ravulizumab Significantly Reduces Relapses in NMOSD Trial
The phase 3 CHAMPION-NMOSD trial evaluated ravulizumab-cwvz, a C5 complement inhibitor, in 58 adults with AQP4 Ab+ NMOSD.
Two Acute Symptoms May Predict Prolonged Concussion Recovery
Feeling like ‘in a fog’ and sadness may predict symptoms lasting 28 days or longer following a sport-related concussion
Supernus One Step Closer to Decision on Apomorphine Infusion Device
SPN-830 provides a continuous subcutaneous infusion of apomorphine through an infusion pump.
Sterility Issue Prompts Recall of Injectable Antiepileptic Drug
The recalled lots of Levetiracetam Injection 500mg per 5mL; NDC Number 25021-780-05, were distributed nationwide from March to November 2021.
Eprontia Oral Solution Approved for Partial-Onset, Primary Generalized Tonic-Clonic Seizures
Eprontia is approved for the treatment of partial-onset or primary generalized tonic-clonic seizures and migraine prevention.
Traumatic Brain Injury Tied to Later Opioid Use, Misuse
History of TBI tied to 52 percent increased odds of prescription opioid use, 65 percent increased odds of prescription opioid misuse
First-of-its-Kind Deep Brain Stimulation Directional Lead Approved
The system works with Medtronic’s Percept™ PC Neurostimulator.
NeuroSphere Virtual Clinic Allows for Remote Neuromodulation Therapy Management
Using the programmer app, clinicians are able to remotely prescribe new treatment settings to the patient’s neuromodulation device via cloud and Bluetooth-based technology.
